Agigma is a preclinical stage specialty pharma company that uses proprietary nanofiber technology to develop and manufacture dermatology and transdermal products:
-
We reformulate dermatology drugs to enhance their efficacy, reduce side effects and improve aesthetics
-
We enable transdermal delivery of low solubility, poor absorption drugs and biologics
PROBLEM
Lack of drug dose control results in efficacy and safety issues.
Adverse side effectsand poor product aesthetics result in patient compliance issues.
Incompatibility of drugs with product technologies results in limited access to therapeutic areas and markets.
OUR SOLUTION
Nanofiber formulations offer improved efficacy and safety.
Nanofiber products feature less side effects and improved aesthetics.
Nanofibers enable transdermal delivery of low solubility, poor absorption drugs and biologics.
|
Our mission is to improve quality of care with specialty products for delivery of drugs via skin.
Our vision is to provide innovative, effective and safe products for dermatology and transdermal delivery.
|
|
